Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 12/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25957274 | 1.00 | NR1H2 (0.46) | NR1H2BRD4SRCCYP1A2POLB | |
| SCHEMBL30543805 | 0.89 | BRD4 (0.40) | NR1H2BRD4SRCCYP1A2POLB | |
| SCHEMBL1710964 | 0.86 | NR1H2 (0.56) | NR1H2SRCCYP1A2POLBCYP3A4 | |
| SCHEMBL21845181 | 0.83 | NR1H2 (0.48) | NR1H2SRCCYP1A2POLBCYP3A4 | |
| SCHEMBL21845527 | 0.83 | NR1H2 (0.48) | NR1H2SRCCYP1A2POLBCYP3A4 | |
| SCHEMBL21887306 | 0.83 | NR1H2 (0.48) | NR1H2SRCCYP1A2POLBCYP3A4 | |
| SCHEMBL30543976 | 0.83 | BRD4 (0.42) | NR1H2BRD4CYP1A2POLBCYP3A4 | |
| SCHEMBL12808018 | 0.83 | NR1H2 (0.50) | NR1H2SRCCYP1A2POLBCYP3A4 | |
| SCHEMBL1585055 | 0.83 | NR1H2 (0.50) | NR1H2SRCCYP1A2POLBCYP3A4 | |
| SCHEMBL1604339 | 0.83 | NR1H2 (0.50) | NR1H2SRCCYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2025-05-29 | — | — | US | disclosed |
| CN-118974013-A | Pyrrolidine compounds | 伊莱利利公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | SDHA, GMPS, SDHB | NR1H2 3961/4885BRD4 3099/4885SRC 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.